Gold prices edge higher on raised Fed rate cut hopes
WINTER PARK, Florida - Adia Nutrition, Inc. (OTCQB:ADIA), whose stock has surged over 350% year-to-date according to InvestingPro data, announced Wednesday that its subsidiary Adia Med has incorporated glutathione IV therapies into select treatment protocols at its clinics, while simultaneously launching a transdermal glutathione spray through Adia Labs.
The company’s medical division is adding the glutathione IV treatments to complement its existing regenerative medicine protocols, which include stem cell and exosome treatments for orthopedic conditions, pain management, and wound repair. Glutathione, described as a naturally occurring tripeptide that supports cellular health and detoxification, will be administered intravenously at Adia Med clinics. InvestingPro analysis indicates the company maintains a "Fair" financial health score of 1.82, suggesting stable operational capabilities.
Adia Labs’ new Glutaryl Transdermal Spray uses sub-nanotechnology to enhance skin absorption, offering an alternative to IV administration for patients seeking glutathione’s antioxidant benefits.
"We’re thrilled to bring glutathione therapies into Adia’s portfolio, reinforcing our leadership in regenerative medicine," said Larry Powalisz, CEO of Adia Nutrition, in the press release statement.
The company cited market research suggesting the global glutathione market is estimated to reach $3.9 billion by 2035, driven by increasing consumer awareness of antioxidants’ role in health and wellness.
Adia Nutrition operates through multiple divisions, including its supplement division and medical division that specializes in stem cell therapies. The company trades on the OTCQB market under the ticker ADIA at $0.03 per share, with a 173% gain over the past year. Discover more detailed financial metrics and exclusive insights with InvestingPro, including real-time valuation analysis and growth potential indicators.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.